Bionano Genomics to Present at the 32nd Annual Oppenheimer Healthcare Conference
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc.(BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr system and provider of NxClinical, a leading software solution for visualization, interpretation, and reporting of genomic data,announced today that company management will present virtually at the 32nd Annual Oppenheimer Healthcare Conference.
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, a leading software solution for visualization, interpretation, and reporting of genomic data, announced today that company management will present virtually at the 32nd Annual Oppenheimer Healthcare Conference. Erik Holmlin, PhD, Bionano’s president and chief executive officer, is scheduled to present a corporate overview on Tuesday, March 15th, 2022 at 5:40 am PT/8:40 am ET.
The presentation will be available to view on the Events page in the Investors section of Bionano’s website.
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. For more information, visit bionanogenomics.com, lineagen.com or biodiscovery.com.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
[email protected]
Investor Relations:
Amy Conrad
Juniper Point
+1 (858) 366-3243
[email protected]
Media Relations:
Michael Sullivan
Seismic
+1 (503) 799-7520
[email protected]
